An Austrian study of the baseline prevalence of metabolic abnormalities and changes following treatment with five commonly-used antipsychotic drugs (haloperidol, amisulpride, olanzapine, quetiapine or ziprasidone) in first-episode, partially antipsychotic-naive patients with schizophrenia found that the overall prevalence was similar to the rate seen in both antipsychotic-naive patients and the general population. The study, published in the International Journal of Neuropsychopharmacology, found that metabolic risk increased significantly in all groups over the 52-week followup.
Fleischhacker WW, Siu CO, Bodén R, Pappadopulos E, Karayal ON, Kahn RS; Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. International Journal of Neuropsychopharmacology. 2012 Dec 20:1-9. [Epub ahead of print]
